References
- Amin ML. (2013). P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27–34.
- Boffetta P, Nordenvall C, Nyrén O, et al. (2009). A prospective study of gout and cancer. Eur J Cancer Prev 18:127–32.
- Chen J, Lin H, Hu M. (2003). Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther 304:1228–35.
- Cheon JH, Kim KS, Kim M, et al. (2017). The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine. Biochem Biophys Res Commun. [Epub ahead of print]. doi: 10.1016/j.bbrc.2017.06.178.
- Choi HY, Kim SH, Choi AR, et al. (2017). Hyperuricemia and risk of increased arterial stiffness in healthy women based on health screening in Korean population. PLoS One 12:e0180406.
- Ding H. (2004). Modulation of Kupffer cells on hepatic drug metabolism. World J Gastroenterol 10:1325–8.
- Fromm MF. (2003). Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33(Suppl. 2):6–9.
- Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36.
- Glaeser H. (2011). Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 201:285–97.
- Goh LB, Spears KJ, Yao D, et al. (2002). Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64:1569–78.
- Hartz AM, Pekcec A, Soldner EL, et al. (2017). P-gp protein expression and transport activity in rodent seizure models and human epilepsy. Mol Pharm 14:999–1011.
- Hou PY, Mi C, He Y, et al. (2015). Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. Fitoterapia 105:43–8.
- Irvine JD, Takahashi L, Lockhart K, et al. (1999). MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28–33.
- Jeong EJ, Liu Y, Lin H, et al. (2004). In situ single-pass perfused rat intestinal model for absorption and metabolism. In: Yan Z, Caldwell GW, eds. Methods in pharmacology and toxicology optimization in drug discovery: in vitro methods. Totowa: Humana Press Inc., 65–76.
- Jones HM, Houston JB. (2004). Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973–82.
- Li HG, Hou PY, Zhang X, et al. (2016). Hypouricemic effect of allopurinol are improved by Pallidifloside D based on the uric acid metabolism enzymes PRPS, HGPRT and PRPPAT. Fitoterapia 113:1–5.
- Liu H, Ma Z, Wu B. (2013). Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors. Xenobiotica 43:1018–126.
- Liu W, Liu H, Sun H, et al. (2014). Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). Xenobiotica 44:455–64.
- Lowry OH, Rosebrough NJ, Farr AL, et al. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–75.
- Lundquist P, Englund G, Skogastierna C, et al. (2014). Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition. Drug Metab Dispos 42:448–58.
- Madan J, Chawla G, Arora V, et al. (2005). Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J 7:224–30.
- Meng ZQ, Tang ZH, Yan YX, et al. (2014). Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation. Am J Chin Med 42:1471–83.
- Muz B, Kusdono HD, Azab F, et al. (2017). Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Leuk Lymphoma 58:2916–25.
- Nisar A, Akhtar N, Hassan A, et al. (2014). Effect of Ajuga bracteosa on systemic T-cell immunity in Balb/Cmice: dual Th1/Th2 immunostimulatory effects. Am J Chin Med 42:375–92.
- Staud F, Ceckova M, Micuda S, et al. (2010). Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 596:199–222.
- Tachibana T, Kato M, Takano J, et al. (2010). Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 11:762–77.
- Tong XL, Dong L, Chen L, et al. (2012). Treatment of diabetes using traditional Chinese medicine: past, present and future. Am J Chin Med 40:877–86.
- Valenzuela B, Nácher A, Ruiz-Carretero P, et al. (2004). Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J Pharm Sci 93:1641–8.
- Volpe DA. (2011). Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med Chem 3:2063–77.
- Wang CZ, He H, Wang X, et al. (2012). Trends in scientific publications of Chinese medicine. Am J Chin Med 40:1099–108.
- Wang WH, Shao MN, Han YG. (2000). The nutrition composition analysis of Smilax riparia A.D. Spec Wild Econ Anim Plant Res 3:46–7.
- Wu XH, Ruan JL, Zhang J, et al. (2014). Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice. J Ethnopharmacol 157:201–5.
- Wu XH, Wang CZ, Wang SQ, et al. (2015). Anti-hyperuricemia effects of allopurinol are improved by Smilax riparia, a traditional Chinese herbal medicine. J Ethnopharmacol 162:362–8.
- Xu H, Kulkarni KH, Singh R, et al. (2009). Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm 6:1703–15.
- Yang Z, Gao S, Wang J, et al. (2011). Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos 39:1866–72.
- Ye L, Wang T, Tang L, et al. (2011). Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. J Pharm Sci 100:5007–17.
- Zhang SL, Han ZH. (2012). Textural research of categories and functions on Nian-Yu-Xu recorded in Cai-Yao-Lu from Ben-Cao-Gang-Mu-Shi-Yi. J Zhejiang Univ TCM 36:484–6.